Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Autonomous & Electric Vehicles (DRIV) vs Eli Lilly And Co (LLY) Price & Performance

Global X Autonomous & Electric VehiclesTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Global X Autonomous & Electric Vehicles vs Eli Lilly And Co — how do they compare? Global X Autonomous & Electric Vehicles trades at $32.44 (market cap $356.37M), while Eli Lilly And Co trades at $1,166.44 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 2918.3× Global X Autonomous & Electric Vehicles's market cap, and Eli Lilly And Co pays a 0.59% dividend while Global X Autonomous & Electric Vehicles pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Autonomous & Electric Vehicles for 40 Days and Eli Lilly And Co for 93 Days on average.

DRIVLLY
Market Cap
$356.37M$1.04T
Volume
22,3973,064,878
Sector
Sector/ThematicHealth
52-Week High
$42.53$1.28K
52-Week Low
$27.58$799.57
Typical Hold Time
40 Days93 Days
Enterprise Value
—$1.09T
Dividend Yield
—0.59%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Autonomous & Electric Vehicles

DRIV trades at $33.37, down 1.68% today amid mixed technical signals. The overall technical outlook is bullish with neutral oscillators, while key support sits at $33. Recent news highlights automotive sector focus on hybrid and electric vehicles, though company-specific financial ratios are currently unavailable for analysis.

The stock shows technical resilience near support levels with bullish momentum indicators. Investment appeal hinges on forthcoming financial disclosures and sector trends favoring EV/hybrid adoption. Key risks include sector competition and reliance on broader automotive market performance without current fundamental data.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,188.72, up 2.7% on the day, with a bullish technical signal and strong fundamentals. Recent earnings beats, robust revenue growth to $65.18B in 2025, and a net income margin of 33.53% highlight operational strength. Positive news flow centers on next-generation weight-loss drugs, with analyst consensus bullish and a price target of $1,350.

Outlook remains positive given pipeline catalysts in obesity/diabetes markets, though high valuations (P/E 39.9) and rising debt levels pose risks. Competitive intensity and regulatory scrutiny are watchpoints, but institutional support and earnings momentum underpin further upside potential.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DRIV
0% Buy100% Sell
Avg holding period · 40 Days
LLY
69% Buy31% Sell
Avg holding period · 93 Days

Top news

Latest headlines on both assets

About Global X Autonomous & Electric Vehicles

DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.

Read more on DRIV →

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY →